On September 10th, CAR-T therapy expert Curocell, led by CEO Gunsoo Kim, announced the formalization of a strategic partnership through the signing of a Memorandum of Understanding (MOU) with Genscript Probio, headed by CEO Patrick Liu. The collaboration aims to advance the development of next-generation CAR-T therapies, with a specific focus on the manufacturing of viral vectors.

Under this agreement, both entities will engage in a comprehensive strategic collaboration encompassing the research, development, and clinical trials of CAR-T therapies. Viral vectors, integral to CAR-T therapies, serve as virus-based delivery systems for transferring genetic material into cells. The surge in demand for viral vectors aligns with the expanding gene therapy and CAR-T therapy markets.

Patrick Liu, CEO of Genscript Probio, expressed enthusiasm about the MOU, emphasizing the pleasure of partnering with Curocell, a leading CAR-T therapy company in Korea, for the manufacturing and supply of viral vectors. He stated, "I am delighted to establish a close collaborative relationship with Curocell for the production and supply of viral vectors, contributing not only to the Korean market but also to the global advancement of CAR-T therapies. Through this partnership, we will continue working closely with Curocell to facilitate the expansion of CAR-T therapies both domestically and internationally."

Gunsoo Kim, CEO of Curocell, highlighted the collaboration's significance, stating, "Through this agreement, we have forged a robust collaborative foundation spanning the developmental stages to the commercialization of CAR-T therapies." He added, "Curocell aims to emerge as a global leader in anti-cancer immunotherapy through our partnership with Genscript Probio, a globally recognized company in the gene therapy field."